They ended up killing the trial, because the patients liver function tests (LFT's) were very high. These were end stage cancers, so I didn't really understand what the big deal was. These were patients who had been through ever other treatment on the market and were now on to experimental treatments, so their blood chemistry was probably crap already. They were going to get experts together and try to come up with a solution to the liver enzyme problem. Not sure what ever happened with the compound, since I left that company back in '02.
|